Patents Assigned to Monogram Biosciences
-
Publication number: 20070264160Abstract: A microfluidic analytical apparatus (10) comprising a microfluidic card pairing (12) with a corresponding circuit card (14) and the circuit card pairing (12) with corresponding conductive fingers (16). The microfluidic card (12) has a plurality of channels (32) and ports (54) on a top surface of the card in a desired configuration, the ports (54) in fluid communication with the channels (32). The circuit card (14) has a plurality of conductive pins (60) projecting from a bottom surface of the card and having a configuration that corresponds to the particular configuration of the ports (54) of the microfluidic card (12) that is paired with. The circuit card (14) is received within a holder (20) that provides that provides multiple functions.Type: ApplicationFiled: June 11, 2007Publication date: November 15, 2007Applicant: Monogram Biosciences, Inc.Inventors: Torleif Bjornson, Kevin Maher
-
Patent number: 7279585Abstract: Compounds, compositions, and methods for labeling membranes are disclosed. Compounds of formula G-L-E are described wherein G is a lipophilic group, L is a cleavable linkage and E is an electrophoretic group. The compounds become associated with membranes, and can be cleaved with a cleavage-inducing moiety thereby releasing the detectable electrophoretic group.Type: GrantFiled: July 14, 2003Date of Patent: October 9, 2007Assignee: Monogram Biosciences, Inc.Inventors: Sharat Singh, Hasan Tahir
-
Patent number: 7279279Abstract: This invention provides a method for determining susceptibility for an anti-viral drug comprising: (a) introducing a resistance test vector Comprising a patient-derived segment and an indicator gene into a host cell; (b) culturing the host cell from (a); (c) measuring expression of the indicator gene in a target host cell; and (d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the anti-viral drug, wherein a test concentration of the anti-viral drug is present at steps (a)-(c); at steps (b)-(c); or at step (c).Type: GrantFiled: May 14, 2004Date of Patent: October 9, 2007Assignee: Monogram Biosciences, Inc.Inventors: Daniel J. Capon, Christos J. Petropoulos
-
Patent number: 7255999Abstract: Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs. The binding site is the result of post-translational modification activity involving the target polypeptide. The method may be employed to determine the target polypeptide itself. In another embodiment the presence and/or amount of the target polypeptide is related to the presence and/or amount and/or activity of an agent such as an enzyme involved in the post-translational modification of the target polypeptide.Type: GrantFiled: May 21, 2002Date of Patent: August 14, 2007Assignee: Monogram Biosciences, Inc.Inventors: Sharat Singh, Hossein Salimi-Moosavi, Syed Hasan Tahir, Gerald J. Wallweber, Hrair Kirakossian, Tracy J. Matray, Vincent S. Hernandez
-
Patent number: 7247439Abstract: The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the aType: GrantFiled: February 15, 2002Date of Patent: July 24, 2007Assignee: Monogram Biosciences, Inc.Inventors: Douglas Richman, Mary T. Wrin, Susan Little, Christos J. Petropoulos, Neil T. Parkin, Jeannette M. Whitcomb, Wei Huang
-
Patent number: 7235356Abstract: The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the aType: GrantFiled: September 21, 2005Date of Patent: June 26, 2007Assignee: Monogram Biosciences, Inc.Inventors: Christos J. Petropoulos, Neil T. Parkin, Jeanette Whitcomb, Wei Huang
-
Patent number: 7217531Abstract: The present invention is directed to methods and compositions for determining the presence, absence, and/or amounts of one or more membrane-associated analytes in a sample. In accordance with the invention, binding compounds derivatized with releasable molecular tags specifically bind to selected membrane-associated analytes, after which the molecular tags are released upon activation of cleavage moieties, or sensitizers, anchored in the same membrane as the membrane-associated analytes. The released molecular tags are then identified by their distinct separation and detection characteristics.Type: GrantFiled: August 27, 2005Date of Patent: May 15, 2007Assignee: Monogram BiosciencesInventors: Sharat Singh, Po-Ying Chan-Hui, Hrair Kirakossian
-
Patent number: 7186506Abstract: This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), particularly treatment regimens including a protease inhibitor. The invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays.Type: GrantFiled: September 15, 2000Date of Patent: March 6, 2007Assignee: Monogram Biosciences, Inc.Inventors: Neil T. Parkin, Rainer A. Ziermann
-
Patent number: 7169551Abstract: The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the aType: GrantFiled: December 29, 2005Date of Patent: January 30, 2007Assignee: Monogram Biosciences, Inc.Inventors: Christos J. Petropoulos, Neil T. Parkin, Jeanette Whitcomb, Wei Huang
-
Patent number: 7160735Abstract: Compositions and methods are disclosed for detecting multiple target analytes in a sample using microparticles having molecular tags attached by cleavable linkages. Generally, an assay mixture is formed comprising a sample and a reagent comprising multiple such microparticles under conditions that permit stable complexes to form between binding moieties on the surfaces of the microparticles and the analytes. In one aspect of the invention, the a second binding composition is added so that complexes form among the microparticle-bound binding moieties, the analytes, and second binding moieties of the second binding composition. Such second binding moieties have cleavage-inducing moieties attached that upon activation cause the cleavage of the cleavable linkages and the release of molecular tags. Released molecular tags are separated and the presence and/or amount of the target analytes are determined based on the analysis of the released and separated molecular tags.Type: GrantFiled: November 8, 2002Date of Patent: January 9, 2007Assignee: Monogram Biosciences, Inc.Inventors: Peter Dehlinger, Sharat Singh, Hrair Kirakossian
-
Patent number: 7138231Abstract: This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), particularly treatment regimens including a protease inhibitor. The invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays.Type: GrantFiled: January 19, 2001Date of Patent: November 21, 2006Assignee: Monogram Biosciences, Inc.Inventors: Neil T. Parkin, Rainer A. Ziermann
-
Patent number: 7135300Abstract: Methods are provided for detecting formation of oligomeric complexes of molecules on the surface of cell membranes. These methods employ pairs of tagged probes and cleaving probes, each of which binds specificly to a cell surface molecule. The tagged probe includes a molecular tag that is linked to a first binding compound through a cleavable linkage, and the cleaving probe includes a second binding agent and a cleavage-inducing moiety that can cleave the linkage when within a defined proximity thereto. Binding of the two probes to cell surface molecules that have formed an oligomeric complex results in release of the molecular tag from the binding compound, providing a measure of formation of the complex.Type: GrantFiled: April 22, 2004Date of Patent: November 14, 2006Assignee: Monogram Biosciences, Inc.Inventors: Po-Ying Chan-Hui, Yining Shi, Sailaja Pidaparthi, Rajiv Dua, Sharat Singh
-
Patent number: 7122319Abstract: Methods and compositions are provided for detection of analytes, such as cell surface moieties, preferably in multiplexed assays, such that multiple analytes can be assayed simultaneously. The methods employ analyte binding agents which are linked to oligonucleotide labels, which labels are then used for formation of cleavage structures and generation of detectable molecular tags. Preferably, multiple tags are generated per analyte binding event.Type: GrantFiled: November 5, 2003Date of Patent: October 17, 2006Assignee: Monogram Biosciences, IncInventors: Linda Liu, Po-Ying Chan-Hui, Hrair Kirakossian, Sharat Singh
-
Patent number: 7105308Abstract: Methods are provided for detecting formation of oligomeric complexes of molecules on the surface of cell membranes. These methods employ pairs of tagged probes and cleaving probes, each of which binds specificly to a cell surface molecule. The tagged probe includes a molecular tag that is linked to a first binding compound through a cleavable linkage, and the cleaving probe includes a second binding agent and a cleavage-inducing moiety that can cleave the linkage when within a defined proximity thereto. Binding of the two probes to cell surface molecules that have formed an oligomeric complex results in release of the molecular tag from the binding compound, providing a measure of formation of the complex.Type: GrantFiled: July 17, 2003Date of Patent: September 12, 2006Assignee: Monogram Biosciences, Inc.Inventors: Po-Ying Chan-Hui, Yining Shi, Sailaja Pidaparthi, Rajiv Dua, Sharat Singh
-
Patent number: 7097970Abstract: The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the aType: GrantFiled: June 4, 2001Date of Patent: August 29, 2006Assignee: Monogram Biosciences, Inc.Inventors: Christos J. Petropoulos, Neil T. Parkin, Jeanette M. Whitcomb, Wei Huang
-
Patent number: 7045311Abstract: The activity of a cell surface protease, particularly an ADAM, is determined in a rapid and sensitive assay employing a whole cell system. The assays are effective to identify effector molecules that affect the activity of a cell surface protease directly or indirectly, and to screen for therapeutic agents that modulate those effector molecules. The assays can also be used to screen for therapeutic agents that modulate the activity of a cell surface protease associated with a disease or medical condition. Kits comprising at least one component of the present assays are also provided.Type: GrantFiled: October 25, 2002Date of Patent: May 16, 2006Assignee: Monogram Biosciences, Inc.Inventors: Gary J. Ciambrone, Ian Gibbons
-
Patent number: 7041459Abstract: Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone phosphorylation. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and an IMAC resin for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs. The binding site is the result of phosphorylation activity involving the target polypeptide. The method may be employed to determine the target polypeptide itself. In another embodiment the presence and/or amount of the target polypeptide is related to the presence and/or amount and/or activity of an agent such as an enzyme involved in phosphorylation of the target polypeptide.Type: GrantFiled: May 21, 2002Date of Patent: May 9, 2006Assignee: Monogram Biosciences, Inc.Inventors: Sharat Singh, Robert Allan Zivin